October 21, 2021, 17:22

China’s Sinopharm Developing MRNA COVID-19 Vaccine Against New Variants – Official

China’s Sinopharm Developing MRNA COVID-19 Vaccine Against New Variants – Official

BEIJING (Sputnik) – Chinese pharmaceutical company Sinopharm is working on a second-generation mRNA COVID-19 vaccine against new virus variants, Zhu Jingjin, the secretary of the party committee of a Sinopharm subsidiary, said.

The official from China National Biotec Group told China Central Television in an interview, that Sinopharm had already developed four vaccines including two inactivated, one mRNA vaccine, and one recombinant.

The secretary highlighted that the mRNA vaccine, developed autonomously by China National Biotec Group, is aimed at fighting new COVID-19 variants.

“We all are looking forward for such second-generation vaccine against mutated COVID-19 strains to enter the market as soon as possible, to help the entire world to cope with the pandemic sooner,” the official added.

The inactivated Sinopharm’s vaccine remains effective for six months after two shots, according to Zhu, who indicated that it fully complies with the World Health Organization requirements.

China has been conducting a successful COVID-19 vaccination policy. Over 2.1 billion vaccine doses have been administered in the country.

Sourse: sputniknews.com

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *